Showing 1 - 6 results of 6 for search 'Stephan Bart', query time: 0.03s Refine Results
  1. 1
    Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults

    Safety and immunogenicity of heterologous Ad26.ZEBOV and MVA-BN®-Filo prime-boost Ebola vaccines: 6-month follow-up of a Phase I randomized trial in healthy adults by Macaya Douoguih, Neil Goldstein, Stephan Bart, Kerstin Luhn, Wilbert Van Duijnhoven, Carla Truyers, Benoit Callendret

    Published 2016-05-01
    Get full text
    Article
  2. 2
    A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.

    A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever. by Robert T Cartee, Ann Thanawastien, Thomas J Griffin Iv, John J Mekalanos, Stephan Bart, Kevin P Killeen

    Published 2020-01-01
    Get full text
    Article
  3. 3
    Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen

    Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen by Viki Bockstal, Auguste Gaddah, Neil Goldstein, Georgi Shukarev, Stephan Bart, Kerstin Luhn, Cynthia Robinson, Dickson Anumendem, Maarten Leyssen, Macaya Douoguih

    Published 2021-12-01
    Get full text
    Article
  4. 4
    Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial

    Safety and Immunogenicity of a Novel Intranasal Influenza Vaccine (NasoVAX): A Phase 2 Randomized, Controlled Trial by Sybil Tasker, Anna Wight O’Rourke, Anvar Suyundikov, Peta-Gay Jackson Booth, Stephan Bart, Vyjayanthi Krishnan, Jianfeng Zhang, Katie J. Anderson, Bertrand Georges, M. Scot Roberts

    Published 2021-03-01
    Get full text
    Article
  5. 5
    First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study

    First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered i... by Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Auguste Gaddah, Dickson Anumenden, Jeroen N. Stoop, Anne Marit de Groot, Maria G. Pau, Jenny Hendriks, Stephen C. De Rosa, Kristen W. Cohen, M. Juliana McElrath, Benoit Callendret, Kerstin Luhn, Macaya Douoguih, Cynthia Robinson

    Published 2022-01-01
    Get full text
    Article
  6. 6
    First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.

    First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered i... by Viki Bockstal, Georgi Shukarev, Chelsea McLean, Neil Goldstein, Stephan Bart, Auguste Gaddah, Dickson Anumenden, Jeroen N Stoop, Anne Marit de Groot, Maria G Pau, Jenny Hendriks, Stephen C De Rosa, Kristen W Cohen, M Juliana McElrath, Benoit Callendret, Kerstin Luhn, Macaya Douoguih, Cynthia Robinson

    Published 2022-01-01
    Get full text
    Article

Search Tools: